Lixte Non Currrent Assets Other from 2010 to 2024

LIXTW Stock  USD 0.02  0.00  0.00%   
Lixte Biotechnology Non Currrent Assets Other yearly trend continues to be fairly stable with very little volatility. Non Currrent Assets Other are likely to outpace its year average in 2024. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
2006-06-30
Previous Quarter
78 K
Current Value
6.9 K
Quarterly Volatility
99.2 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Non Currrent Assets Other Growth Pattern

Below is the plot of the Non Currrent Assets Other of Lixte Biotechnology Holdings over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Lixte Biotechnology's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other10 Years Trend
Slightly volatile
   Non Currrent Assets Other   
       Timeline  

Lixte Non Currrent Assets Other Regression Statistics

Arithmetic Mean43,312
Geometric Mean10,394
Coefficient Of Variation129.44
Mean Deviation49,223
Median2,293
Standard Deviation56,063
Sample Variance3.1B
Range147.9K
R-Value0.81
Mean Square Error1.2B
R-Squared0.65
Significance0.0003
Slope10,095
Total Sum of Squares44B

Lixte Non Currrent Assets Other History

2024100 K
202378 K
2022147 K
2021150.2 K
201976.9 K

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Currrent Assets Other78 K100 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.